Items with tag "cell therapy"

News

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

While C-Cure had failed an essential phase 3 clinical trial in June last year, the trial identified a subgroup of patients where the drug was effective nonetheless. Based on this fact, C-Cure now …

Read more

Novartis takes license on Celyad's allogeneic CAR T cells

Celyad, a leader in the discovery and development of cell therapies, today announced a non-exclusive license agreement with Novartis for Celyad’s US patents for the production of allogeneic CAR T …

Read more

TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction

TiGenix, stem cell specialist focused on developing novel therapeutics from its two proprietary platforms of donor-derived expanded adipose derived stem cells (eASC) and donor-derived expanded car…

Read more

Cell therapy for Crohn's disease gets FDA boost to enter US market

TiGenix NV, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cells, announced today that it has r…

Read more

Continued coverage of Celyad's Patent assured

Celyad announced today that the U.S. Patent and Trade Office (USPTO) has decided to uphold Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary T-cells that are engineered to b…

Read more

Bone Therapeutics Granted EUR 2.3 Million by the Walloon Region

Bone cell therapy company Bone Therapeutics receives 2.3 million in funding from the Wallonian Government.

Read more

Celyad Announces Registration of the first patient in the Belgian THINK trial

Celyad commences THINK trial with its cell-based CAR-T/NKR-2 immunotherapy 

Read more

Celyad cuts deal with Ono Pharmaceutical on immunotherapy treatment

Japan's Ono Pharmaceutical will license a cancer treatment of Celyad. The collaboration is very welcome, as two weeks ago, the Walloon company had to share disappointing results of C-Cure, a stem …

Read more

TiGenix inks massive deal with Takeda

Today cell therapy specialist TiGenix has disclosed a new deal with the Japanese pharmaceutical giant Takeda. The agreement allows Takeda the rights to license, develop and sell TiGenix’ Cx601 glo…

Read more

Celyad's cardiac stem cell treatment fails phase III clinical trials

Celyad’s cardiac therapy C-Cure® failed to show a significant benefit in the CHART-1 phase III clinical study. C-Cure is an experimental treatment based on stem cells that produce new autologous h…

Read more

Stem cells in baby urine to treat kidney disease

Patients with a kidney disease or injury can sometimes be helped with a specific type of stem cells. An international team led by Professor Elena Levtchenko from KU Leuven has now discovered that …

Read more

Tigenix goes American

Since 2007, Tigenix is listed on the Euronext Brussels stock exchange. Now, the Leuven-based company wants to expand its reach and has announced a request for registration on the American Nasdaq s…

Read more

Jackpot for TiGenix' sepsis research

The biotech company TiGenix gets financial support in his search for a cure for severe sepsis due to pneumonia. The European Commission granted the Leuven-based company and its partners an amount …

Read more

Bone Therapeutics grows both locally and internationally to become a champion of bone regenerative medicine

Walloon bone cell therapy company, Bone Therapeutics (BOTHE), is moving into their new headquarters in Gosselies. The new 3000m² facility is part of a larger project, the Walloon Cell Therapy Plat…

Read more

Phase I favorable results for TiGenix’ sepsis drug

TiGenix is developing a drug based on allogeneic expanded adipose-derived stem cells (eASCs) to treat artritis and sepsis. The Phase I trials confirmed the safety and tolerability of the drug. …

Read more

Insights

Stem cell patch restores vision to the blind

Stem cell patch restores vision to the blind

A stem cell patch has successfully restored sight to two blind patients in the UK. The Phase I trial is the first of its kind to use a whole engineered piece of tissue to treat vision impairment. …

Read more

Growing organs in the lab: science or science fiction?

Growing organs in the lab: science or science fiction?

Catherine Verfaillie was very close to being an Olympic athlete in heptathlon, but due to a major knee injury, she had to switch from studying physical education to medicine in her first year of u…

Read more

Celyad: CAR-T cells with natural killer skills fight cancer

Celyad: CAR-T cells with natural killer skills fight cancer

Celyad, based in Mont-Saint-Guibert (Belgium), was originally established in 2004 as a company active in regenerative cell therapy. However, two years ago, Celyad decided to move into immuno-oncol…

Read more

Dendritic cells boosted with mRNA form promising cancer immunotherapy

Dendritic cells boosted with mRNA form promising cancer immunotherapy

With its expertise in mRNA production and knowledge of the biology of dendritic cells, eTheRNA has developed TriMix, a new mRNA technology platform. TriMix consists of a cocktail of three mRNAs, w…

Read more

Cell therapy for bone injuries - Wim Goemaere

Cell therapy for bone injuries - Wim Goemaere

Bone Therapeutics started as a spin-off from the ULB in 2006. Prof. Valérie Gangji and Dr. Enrico Bastianelli founded the company to develop cell therapies for application in the field of fracture…

Read more

The success of adipose stem cells

The success of adipose stem cells

Cell therapy specialist TiGenix has announced that their product for the treatment of complex perianal fistulas, Cx601, has met the primary endpoint of their European phase three clinical trial. T…

Read more

Challenges for the cell therapy industry

Challenges for the cell therapy industry

In an exclusive interview, Hugues Bultot, Chief Executive Officer of MaSTherCell, an emerging pioneer in the industrialization of cell-based therapeutics, based in Gosselies (Belgium) shares with …

Read more

Regenerative cells for treatment of Duchenne muscular dystrophy

Regenerative cells for treatment of Duchenne muscular dystrophy

Recent research conducted by Marinee Chuah and Thierry VandenDriessche (Gene Therapy and Regenerative Medicine) is being featured on the cover of the latest issue of Nature Protocols. They provide…

Read more

World’s first regenerative product for heart failure

World’s first regenerative product for heart failure

Celyad developed a breakthrough Cardiopoiesis platform designed to differentiate stem cells into cardiac cells to treat heart failure and acute myocardial infarction. The lead product, C-Cure® is …

Read more

Stem Cell Therapy is big in Wallonia

Stem Cell Therapy is big in Wallonia

What do Bone Therapeutics, Cardio3 Biosciences and Imcyse all have in common? They focus on stem cell therapy and are all linked to the Laboratory of Cell and Gene Therapy (LTCG) led by Yves Begui…

Read more

Walloon Cell Therapy Platform for mass production

Walloon Cell Therapy Platform for mass production

As the foundation for the new Walloon Cell Therapy Platform begins to set in Gosselies, Wallonia gets excited about this new development. The platform, unique in this sector, will provide Wallonia…

Read more

I was published in Nature!

I was published in Nature!

Peter Vandenabeele is senior full professor at the Inflammation Research Center (IRC), a VIB department at the Ghent University. He recently published in Nature an original research paper on the r…

Read more

IPO Bone Therapeutics yields 32.2 million euro

IPO Bone Therapeutics yields 32.2 million euro

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises 32.2 million euro in a 2.5 times oversubscribed successful IPO o…

Read more

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

V-Bio Ventures Biowin Itera Life Science Janssen GSK Turnstone XpandInnovation KU Leuven UGent Flanders.bio

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.